HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270

Benzinga · 3d ago
HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.